Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1161/JAHA.120.021154 http://scihub22266oqcxt.onion/10.1161/JAHA.120.021154 34320843!8475700!34320843     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Am+Heart+Assoc 2021 ; 10 (15): e021154 Nephropedia Template TP {{tp|p=34320843|t=2021. Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19 |pdf=|usr=}}{{34320843}} gab.com Text Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19 JO: J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=34320843 #FOAvip Background Considering the widespread risk of collider bias and confounding by indication in previous research, the associations between renin-angiotensin aldosterone system (RAAS) inhibitor use and COVID-19 remain unknown. Accordingly, this study tested the hypothesis that RAAS inhibitors influence the summation effect of COVID-19 and its progression to severe outcomes. Methods and Results This nationwide cohort study compared all residents of Sweden, without prior cardiovascular disease, in monotherapy (as of January 1, 2020) with a RAAS inhibitor to those using a calcium channel blocker or a thiazide diuretic. Comparative cohorts were balanced using machine-learning-derived propensity score methods. Of 165 355 people in the analysis (51% women), 367 were hospitalized or died with COVID-19 (246 using a RAAS inhibitor versus 121 using a calcium channel blocker or thiazide diuretic; Cox proportional hazard ratio [HR], 0.97; 95% CI, 0.74-1.27). When each outcome was assessed separately, 335 people were hospitalized with COVID-19 (HR, 0.92; 95% CI, 0.70-1.22), and 64 died with COVID-19 (HR, 1.22; 95% CI, 0.68-2.19). The severity of COVID-19 outcomes did not differ between those using a RAAS inhibitor and those using a calcium channel blocker or thiazide diuretic (ordered logistic regression odds ratio, 1.01; 95% CI, 0.89-1.14). Conclusions Despite potential limitations, this study is among the best available evidence that RAAS inhibitor use in primary prevention does not increase the risk of severe COVID-19 outcomes; presenting strong data from which scientists and policy makers alike can base, with greater confidence, their current position on the safety of using RAAS inhibitors during the COVID-19 pandemic. Twit Text FOAVip Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19 ????J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=34320843 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34320843 #FOAvip English Wikipedia <ref>{{Cite pmid|34320843}}</ref> Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19 #MMPMID34320843 Loader J; Lampa E; Gustafsson S; Cars T; Sundstrom J J Am Heart Assoc 2021[Aug]; 10 (15): e021154 PMID34320843show ga Background Considering the widespread risk of collider bias and confounding by indication in previous research, the associations between renin-angiotensin aldosterone system (RAAS) inhibitor use and COVID-19 remain unknown. Accordingly, this study tested the hypothesis that RAAS inhibitors influence the summation effect of COVID-19 and its progression to severe outcomes. Methods and Results This nationwide cohort study compared all residents of Sweden, without prior cardiovascular disease, in monotherapy (as of January 1, 2020) with a RAAS inhibitor to those using a calcium channel blocker or a thiazide diuretic. Comparative cohorts were balanced using machine-learning-derived propensity score methods. Of 165 355 people in the analysis (51% women), 367 were hospitalized or died with COVID-19 (246 using a RAAS inhibitor versus 121 using a calcium channel blocker or thiazide diuretic; Cox proportional hazard ratio [HR], 0.97; 95% CI, 0.74-1.27). When each outcome was assessed separately, 335 people were hospitalized with COVID-19 (HR, 0.92; 95% CI, 0.70-1.22), and 64 died with COVID-19 (HR, 1.22; 95% CI, 0.68-2.19). The severity of COVID-19 outcomes did not differ between those using a RAAS inhibitor and those using a calcium channel blocker or thiazide diuretic (ordered logistic regression odds ratio, 1.01; 95% CI, 0.89-1.14). Conclusions Despite potential limitations, this study is among the best available evidence that RAAS inhibitor use in primary prevention does not increase the risk of severe COVID-19 outcomes; presenting strong data from which scientists and policy makers alike can base, with greater confidence, their current position on the safety of using RAAS inhibitors during the COVID-19 pandemic. |*COVID-19/epidemiology/prevention & control[MESH] |*Risk Assessment/methods/statistics & numerical data[MESH] |Aged[MESH] |Angiotensin Receptor Antagonists/*therapeutic use[MESH] |Angiotensin-Converting Enzyme Inhibitors/*therapeutic use[MESH] |Antihypertensive Agents/classification/therapeutic use[MESH] |Calcium Channel Blockers/therapeutic use[MESH] |Female[MESH] |Humans[MESH] |Hypertension/*drug therapy/epidemiology/prevention & control[MESH] |Male[MESH] |Middle Aged[MESH] |Outcome Assessment, Health Care[MESH] |Renin-Angiotensin System/drug effects[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Sodium Chloride Symporter Inhibitors/therapeutic use[MESH]Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention (epmc).pdf DeepDyve Pubget Overpricing